10-K: Oruka Therapeutics Reports 2025 Annual Results, Advances Pipeline

Oruka Therapeutics, a clinical-stage biopharmaceutical company, reported a net loss of $105.4 million for 2025, while advancing its lead programs ORKA-001 and ORKA-002 in psoriasis and other inflammatory indications.

Summary

• Oruka Therapeutics is a clinical-stage biopharmaceutical company focused on developing novel monoclonal antibody therapeutics for psoriasis (PsO) and other inflammatory and immunology (I&I) indications.
• The company's strategy involves applying antibody engineering and format innovations to validated modes of action to improve efficacy and dosing regimens.
• Lead program, ORKA-001, targets IL-23p19 for PsO, incorporating YTE half-life extension technology for potential once or twice-yearly subcutaneous injection.
• Co-lead program, ORKA-002, targets IL-17A and IL-17F for PsO, hidradenitis suppurativa (HS), psoriatic arthritis (PsA), and other conditions, also with half-life extension technology.
• ORKA-001 Phase 1 interim results (September 2025) showed a human half-life of approximately 100 days, complete and sustained inhibition of STAT3 signaling through 24 weeks, and a favorable safety profile.
• ORKA-001 Phase 2a (EVERLAST-A) dosing commenced in Q3 2025, enrolling 84 patients, with Week 16 data expected in Q2 2026 and longer-term data in H2 2026.
• ORKA-001 Phase 2b (EVERLAST-B) dosing commenced in December 2025, designed to enroll 160 patients, with data anticipated in 2027.
• ORKA-002 Phase 1 interim results (January 2026) showed a half-life of approximately 75-80 days, potent and sustained inhibition of IL-17 signaling through 24 weeks, and a favorable safety profile.
• ORKA-002 Phase 2 (ORCA-SURGE) initiated in February 2026, enrolling 160 patients for PsO, with data anticipated in 2027.
• A Phase 2 trial of ORKA-002 in HS is expected to initiate in H2 2026.
• The company also has a third program, ORKA-003, designed to target an undisclosed pathway for indication expansion.
• Net loss for the year ended December 31, 2025, was $105.4 million, compared to $83.7 million for the period from February 6, 2024 (inception) to December 31, 2024.
• Cash, cash equivalents, and marketable securities totaled $479.6 million as of December 31, 2025.
• The company expects existing cash to fund operations for at least 12 months from the filing date.

Sentiment

Score: 6

Explanation: StockSavvy.ai views this as a moderately positive update for a clinical-stage biotech. While significant losses continue, the company has successfully advanced two lead programs into Phase 2 trials with promising interim Phase 1 data, and has a strong cash position to fund operations for the next 12 months, supported by recent capital raises. The increased losses are typical for a company at this stage of development.

Positives

• Successful interim Phase 1 results for ORKA-001, demonstrating a human half-life of approximately 100 days and sustained inhibition of STAT3 signaling through 24 weeks, with a favorable safety profile.
• Initiation of Phase 2a (EVERLAST-A) and Phase 2b (EVERLAST-B) clinical trials for ORKA-001 in moderate-to-severe PsO, testing potential for yearly dosing and extended off-treatment remissions.
• Positive interim Phase 1 results for ORKA-002, showing a half-life of approximately 75-80 days (greater than three times that of bimekizumab) and potent, sustained inhibition of IL-17 signaling through 24 weeks, with a favorable safety profile.
• Initiation of Phase 2 (ORCA-SURGE) for ORKA-002 in moderate-to-severe PsO and plans for a Phase 2 trial in HS, indicating pipeline progression.
• Strong cash position of $479.6 million as of December 31, 2025, expected to fund operations for at least 12 months.
• Strategic focus on inflammatory and immunology (I&I) diseases, leveraging validated mechanisms of action with advanced antibody engineering.
• Potential for ORKA-001 to achieve higher response rates (PASI 100) and less frequent dosing (once or twice per year) compared to established IL-23 therapies.
• Potential for ORKA-002 to enable twice-yearly maintenance dosing in PsO and quarterly in HS, improving convenience over existing IL-17 therapies.
• Development of ORKA-021, a sequential combination regimen of ORKA-002 and ORKA-001, aiming to combine rapid response with superior maintenance.
• Intellectual property protection with patents for ORKA-001 expected to expire in 2045 and ORKA-002 patents, if issued, also in 2045.

Negatives

• Significant net loss of $105.4 million for the year ended December 31, 2025, an increase from $83.7 million in the prior period.
• Accumulated deficit of $189.2 million as of December 31, 2025.
• No revenue generated from product sales to date, and profitability is not expected for the foreseeable future.
• Substantial increase in research and development expenses by $25.6 million (34%) and general and administrative expenses by $8.3 million (64%) year-over-year.
• Reliance on third-party manufacturers and CROs, which introduces supply chain and compliance risks.
• The company will need to secure additional financing in the future beyond the current 12-month runway.
• The long-term safety and efficacy of half-life extension technologies, especially in I&I indications, are still unknown.
• Potential for competition from other companies developing or marketing treatments for the same indications.

Risks

• Limited operating history and no products approved for commercial sale.
• Anticipated continued significant losses for the foreseeable future; may never be profitable.
• Inability to raise additional capital on acceptable terms, leading to curtailment or cessation of product development.
• Raising additional capital may cause dilution to stockholders, restrict operations, or require relinquishing rights to technologies/product candidates.
• Drug development and regulatory approval processes are costly, time-consuming, and highly uncertain.
• Substantial dependence on the success of ORKA-001 and ORKA-002; projected development goals may not be met.
• Competition from entities with greater financial resources and expertise.
• Failure to meet chemistry, manufacturing, and control requirements.
• Lengthy and unpredictable FDA and foreign regulatory approval processes, potentially leading to delays or failure to obtain approval.
• Ongoing regulatory obligations and review post-approval, which could result in restrictions, expenses, and penalties.
• Drug delivery devices may have their own regulatory, development, supply, and other risks.
• The approach to discovery and development using half-life extension technologies is unproven, and may not result in viable programs or demonstrate expected properties in humans.
• Preclinical and clinical development involves lengthy, expensive processes with uncertain outcomes; earlier results may not be predictive.
• Clinical trials may reveal significant adverse events, undesirable side effects, or patient intolerance not previously seen.
• Risk of expending limited resources on less profitable programs.
• Approved products may not achieve adequate market acceptance.
• Certain programs may compete with other company programs, negatively impacting business and revenue.
• Conducting clinical trials outside the U.S. exposes the company to additional operational and regulatory risks.
• Product candidates intended for approval as biologics may face competition sooner than anticipated due to biosimilar pathways.
• Disruptions or changes at the FDA, SEC, and other government agencies could hinder their ability to function, impacting the business.
• Difficulties from legislative or regulatory reform measures, including price controls or other price-limiting strategies.
• Business operations and arrangements with healthcare professionals are subject to healthcare regulatory laws, including conflicts of interest rules, exposing the company to penalties.
• Unfavorable pricing regulations and/or third-party coverage and reimbursement policies could prevent competitive pricing.
• Subject to U.S. and foreign export/import controls, sanctions, embargoes, anti-corruption, and anti-money laundering laws.
• Governments outside the U.S. tend to impose strict price controls.
• Uncertainty in obtaining, maintaining, and protecting patents and other proprietary rights, leading to possible loss of competitive advantage.
• Risk of not identifying relevant third-party patents or incorrectly interpreting their relevance, scope, or expiration.
• Claims challenging inventorship or ownership of intellectual property.
• Inadequate patent terms to protect competitive position.
• Technology licensed from third parties may be subject to retained rights.
• Reliance on third parties to conduct and support preclinical studies and clinical trials; failure of these parties could adversely affect timelines.
• Reliance on third parties to manufacture product candidates; difficulties in production could adversely affect the business.
• Business disruptions to third-party providers (e.g., due to BIOSECURE Act, trade restrictions) could increase costs or delay operations.
• Difficulties in managing growth and attracting/retaining highly qualified personnel.
• Exposure to costly and damaging product liability claims.
• Litigation costs and outcomes could have a material adverse effect.
• Adverse effects from economic downturns, inflation, interest rate fluctuations, natural disasters, public health crises, political crises, geopolitical events.
• Market price of common stock has been, and may continue to be, volatile.
• Provisions in corporate documents and Delaware law could make company acquisition more difficult.
• Future sales of shares by existing stockholders could cause stock price to decline.
• No anticipated cash dividends in the foreseeable future.
• Executive officers, directors, and principal stockholders have significant control/influence.
• Lack of equity research analyst coverage could cause stock price/trading volume to decline.

Future Outlook

The company anticipates continued substantial losses for the foreseeable future as it invests in research and development, advances product candidates into larger clinical trials, and prepares for potential commercialization. It expects its existing cash, cash equivalents, and marketable securities of $479.6 million to fund operating plans for at least 12 months from the filing date. The company plans to share Week 16 data for ORKA-001 EVERLAST-A in Q2 2026, longer-term data in H2 2026, and data from ORKA-001 EVERLAST-B and ORCA-SURGE (ORKA-002) in 2027. A Phase 2 trial of ORKA-002 in HS is expected to initiate in H2 2026. The overall development program for PsO, from first-in-human studies through BLA submission, could take six to seven years.

Management Comments

• "Our name is derived from or, for skin, and arukah, for restoration, and reflects our mission to deliver therapies for chronic skin diseases that provide patients the most possible freedom from their condition."
• "We believe that our focused strategy, differentiated portfolio, and deep expertise position us to set a new treatment standard in large I&I markets with continued unmet need."
• "Based on clinical evidence, we believe that ORKA-001 could achieve higher response rates than established therapies in PsO while requiring less frequent dosing and maintaining the favorable safety profile of therapies targeting IL-23p19."
• "We believe that the anticipated characteristics of ORKA-001 enhance its potential to deliver these disease-modifying benefits."
• "We believe this data supports the key ways in which ORKA-001 could re-define the treatment paradigm in psoriasis: annual dosing, higher efficacy, and off-treatment remission."
• "By binding IL-17A/F at similar epitopes and affinity ranges as Bimzelx while incorporating half-life extension technology to potentially enable twice-yearly maintenance dosing in PsO and quarterly maintenance dosing in HS, we believe that ORKA-002 could become the leading therapy in the IL-17 class."
• "We see ORKA-002 as highly complementary to ORKA-001, with the potential to provide an improved therapy for the approximately one-quarter to one-third of moderate-to-severe PsO patients who have PsA, as well as for PsO patients with highly resistant skin symptoms that do not respond adequately to an IL-23 inhibitor."
• "We believe that ORKA-001 and ORKA-002 provide the potential to offer a highly compelling product profile for most patients with PsO and/or PsA, as well as the opportunity to address additional I&I indications."
• "We believe that a better biologic with a longer dosing interval and the potential for improved efficacy will present a more attractive product profile for most patients."
• "We believe that ORKA-001 and ORKA-002 could represent the next step in biologic innovation in PsO, with the potential for higher rates of complete skin clearance, more durable remissions, and markedly more convenient dosing regimens."
• "We believe that this target profile for ORKA-001 could offer improved freedom from disease to many patients affected by PsO and represent a step forward in the standard of care."
• "Our management believes that there are currently no claims or actions pending against us, the ultimate disposition of which could reasonably be expected to have a material adverse effect on our results of operations, financial condition or cash flows."

Industry Context

StockSavvy.ai notes that Oruka Therapeutics is strategically positioning itself in the competitive inflammatory and immunology (I&I) market by focusing on validated mechanisms (IL-23 and IL-17) but aiming for differentiated product profiles through advanced antibody engineering and half-life extension technology. This approach seeks to improve upon the efficacy and dosing convenience of existing standard-of-care biologics, which is a key driver of commercial success in this market. The company's dual focus on IL-23 and IL-17 inhibitors, along with a planned sequential combination (ORKA-021), reflects an understanding of the diverse patient needs within psoriatic diseases and other I&I indications. The market for psoriasis treatments alone is substantial, estimated at $28 billion in 2024 and projected to grow to $40 billion by 2032, indicating significant commercial opportunity for innovative therapies.

Comparison to Industry Standards

• ORKA-001 aims for once or twice-yearly subcutaneous dosing, significantly less frequent than standard-of-care IL-23 therapies like Skyrizi (risankizumab) and Tremfya (guselkumab), which require maintenance dosing every eight to twelve weeks.
• ORKA-001 is designed to bind similar epitopes and at similar or greater affinities as Skyrizi, with the goal of maximizing efficacy, potentially achieving higher PASI 100 rates through increased exposure. Skyrizi achieved 43% PASI 100 at 16 weeks and 58% at 52 weeks in Phase 3 trials.
• ORKA-002's half-life of 75-80 days is greater than three times that of bimekizumab, supporting potential twice-yearly maintenance dosing in PsO and quarterly in HS, compared to Bimzelx's Q8W dosing in PsO and Q4W in PsA.
• Bimzelx (bimekizumab) has shown higher efficacy than IL-23 inhibitors, achieving a 64% PASI 100 rate at 16 weeks in Phase 3 trials, but with a less convenient Q8W dosing schedule and increased risk of oral candidiasis. ORKA-002 aims to match or exceed this efficacy with better dosing convenience.
• The company's strategy to combine rapid response (IL-17 inhibition) with superior maintenance (IL-23 inhibition) through ORKA-021 aims to address limitations of current monotherapies, where IL-17 inhibitors offer rapid onset but IL-23 inhibitors offer longer remissions.
• The overall development program timeline of six to seven years from first-in-human to BLA submission for PsO is based on averages observed for recently approved medicines, suggesting an aggressive but potentially achievable timeline if trials proceed smoothly.

Management Changes

Corporate Governance

Legal Proceedings

• Management believes there are currently no claims or actions pending against the company that could reasonably be expected to have a material adverse effect on results of operations, financial condition, or cash flows.

Related Party Transactions

• Paragon Therapeutics, Inc. and Paruka Holding LLC (Paruka) are related parties, with Fairmount Funds Management LLC (Fairmount) having significant beneficial ownership in both Oruka and Paragon, and a representative on Oruka's Board.
• The company entered into two Antibody Discovery and Option Agreements with Paragon and Paruka in March 2024.
• Exclusive license agreements were entered with Paragon for ORKA-001 (December 2024) and ORKA-002 (February 2025), involving potential milestone payments of up to $12.0 million for clinical development and up to $10.0 million for regulatory milestones for each program, plus low single-digit percentage royalties on sales.
• Milestone payments incurred/expensed as of December 31, 2025, include $7.0 million for ORKA-001 and $4.0 million for ORKA-002 to Paragon.
• In December 2025, an additional option agreement for an antibody was entered into and exercised with Paragon and Paruka, incurring $1.5 million in R&D expense, with potential future milestone payments and royalties.
• Warrants were issued to Paruka under the Paruka Warrant Obligation: 596,930 shares at an exercise price of $19.39 on December 31, 2024, and 375,000 shares at an exercise price of $30.18 on December 12, 2025.
• A Convertible Note with an initial principal of $25.0 million was issued to Fairmount in March 2024, which converted into common stock upon the merger.

Stakeholder Impact

• Shareholders face potential dilution from recent and future equity raises (PIPE financings, ATM offering) and market price volatility. No cash dividends are anticipated in the foreseeable future. Executive officers, directors, and principal stockholders retain significant influence over company matters.
• Employees benefit from the company's growth, with increased hiring in R&D and administrative roles, competitive compensation, benefits, and professional development opportunities. Stock-based compensation is a significant part of their remuneration.
• Future patients (customers) could benefit from improved therapies for chronic skin diseases like PsO, HS, and PsA, potentially offering better efficacy, less frequent dosing, and durable remissions.
• Creditors are impacted by the company's strong cash position ($479.6 million) providing liquidity, but also by ongoing operating losses and the need for future financing to sustain long-term development.
• Suppliers and contractors, including CROs, CMOs, and Paragon, are critical to the company's R&D and manufacturing. Their performance and compliance, as well as geopolitical factors affecting them (e.g., BIOSECURE Act, trade restrictions), can impact the company's operations and timelines.

Next Steps

• Share Week 16 data for all patients in the ORKA-001 Phase 2a (EVERLAST-A) clinical trial in Q2 2026.
• Share longer-term data, including Week 28 for all patients and 52-week follow-up for a portion of the cohort in the ORKA-001 EVERLAST-A trial in H2 2026.
• Initiate a Phase 2 trial of ORKA-002 in patients with HS in H2 2026.
• Anticipate data from ORKA-001 Phase 2b (EVERLAST-B) trial in 2027.
• Anticipate data from ORCA-SURGE (ORKA-002 Phase 2 PsO) trial in 2027.
• Evaluate a sequential combination regimen of ORKA-002 and ORKA-001 (ORKA-021) in the future.
• Potentially add additional programs to the portfolio beyond ORKA-001, ORKA-002, ORKA-021, and ORKA-003 that fit the strategic focus.
• Secure additional financing in the future to fund further research and development and potential commercialization.

Key Dates

Recommendation

Oruka Therapeutics is making solid progress in its clinical pipeline with promising early-stage data for ORKA-001 and ORKA-002, which leverage half-life extension technology to potentially offer superior dosing convenience and efficacy in large I&I markets. The company has a strong cash position following recent capital raises, providing a runway for at least 12 months. However, it remains a clinical-stage company with no revenue, incurring substantial losses, and faces significant risks inherent in drug development, regulatory approval, and intense competition. The increased losses are expected for a company at this stage but still represent a financial negative. Given the early stage of its lead programs and the inherent uncertainties, a 'hold' recommendation is appropriate for investors to monitor upcoming clinical data readouts and further financial developments before making more aggressive investment decisions.

Keywords

Biopharmaceutical, Monoclonal Antibody, Psoriasis (PsO), Inflammatory & Immunology (I&I), Hidradenitis Suppurativa (HS), Psoriatic Arthritis (PsA), IL-23p19 Inhibitor, IL-17A/F Inhibitor, Half-life Extension, Clinical Trials, ORKA-001, ORKA-002, Drug Development, Biotechnology, SEC Filing, Annual Report, Nasdaq, Fairmount Funds, Paragon Therapeutics